Muhammad S. Beg

1.7k total citations · 1 hit paper
24 papers, 1.2k citations indexed

About

Muhammad S. Beg is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Muhammad S. Beg has authored 24 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Surgery and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Muhammad S. Beg's work include Pancreatic and Hepatic Oncology Research (5 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Genetic factors in colorectal cancer (3 papers). Muhammad S. Beg is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Genetic factors in colorectal cancer (3 papers). Muhammad S. Beg collaborates with scholars based in United States, France and India. Muhammad S. Beg's co-authors include Mitesh J. Borad, Jay Stoudemire, Andrew Brenner, David S. Hong, Yoon‐Koo Kang, Jasgit C. Sachdev, Sinil Kim, Stephen M. Smith, Andreas G. Bader and Amit G. Singal and has published in prestigious journals such as Cancer, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Muhammad S. Beg

24 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

2016 682 citations Muhammad S. Beg, Andrew Brenner et al. Investigational New Drugs profile →

Peers

Countries citing papers authored by Muhammad S. Beg

Since Specialization

Citations

This map shows the geographic impact of Muhammad S. Beg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Muhammad S. Beg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Muhammad S. Beg more than expected).

Fields of papers citing papers by Muhammad S. Beg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Muhammad S. Beg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Muhammad S. Beg. The network helps show where Muhammad S. Beg may publish in the future.

Co-authorship network of co-authors of Muhammad S. Beg

This figure shows the co-authorship network connecting the top 25 collaborators of Muhammad S. Beg. A scholar is included among the top collaborators of Muhammad S. Beg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Muhammad S. Beg. Muhammad S. Beg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trends in Adjuvant Chemotherapy Use Among Stage III Colon Cancer in Non-Elderly and Low Comorbidity Patients 2022 ·Clinical Colorectal Cancer ·(unknown), (unknown), (unknown), Chul Ahn, Nina N. Sanford, Georgios Karagkounis, (unknown), (unknown), (unknown), Radhika Kainthla, David Hsiehchen, (unknown), (unknown), Aravind Sanjeevaiah, Muhammad S. Beg, Emina H. Huang, Syed Mohammad Ali Kazmi	2
2	Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs) 2022 ·Cancer Research ·Joaquina Baranda, Michael S. Gordon, Aparna R. Parikh, Huyuan Yang, Gregory Pennock, Philip Komarnitsky, Muhammad S. Beg	1
3	Current Status and Future Perspectives on the Internet of Things in Oncology 2021 ·Hematology/Oncology and Stem Cell Therapy ·Ibrahim N. Muhsen, (unknown), (unknown), (unknown), (unknown), Md. Abdur Rahman, Douglas Sicker, William A. Wood, Muhammad S. Beg, Anthony D. Sung, Shahrukh K. Hashmi	10
4	Trends of Clinical Outcomes of Patients with Advanced Hepatocellular Carcinoma Treated with First-Line Sorafenib in Randomized Controlled Trials 2021 ·PubMed ·Timothy J. Brown, Arjun Gupta, Ramy Sedhom, Muhammad S. Beg, Thomas B. Karasic, Mark Yarchoan	5
5	Utilizing biofeedback as a behavioral change strategy in overweight and obese cancer survivors to promote physical activity: A focus group analysis 2021 ·(unknown), (unknown), (unknown), M Baum, Muhammad S. Beg, Therese B. Bevers, (unknown), Yi‐Hua Liao	1
6	Early Palliative Care Is Associated With Reduced Emergency Department Utilization in Pancreatic Cancer 2021 ·American Journal of Clinical Oncology ·(unknown), Nizar Bhulani, (unknown), Nina N. Sanford, Ang Gao, Chul Ahn, M. Elizabeth Paulk, (unknown), Sandi L. Pruitt, Anna Tavakkoli, Ramona L. Rhodes, Syed Mohammad Ali Kazmi, Muhammad S. Beg	28
7	536MO A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours 2020 ·Annals of Oncology ·Alex A. Adjei, Muhammad S. Beg, Jason M. Melear, James E. Thompson, (unknown), Joaquina Baranda, Bruno R. Bastos, Alexander I. Spira, Yanyan Lou, Mahesh Seetharam, (unknown), D. Ross Camidge, Nobuyuki Yamamoto, C. Lance Cowey, Toshihiko Doi, Stephen P. Anthony, Margit M. Janát‐Amsbury, Mark Wade, David J. Bearss, John Sarantopoulos	1
8	Trends in Primary Surgical Resection and Chemotherapy for Metastatic Colorectal Cancer, 2000-2016 2020 ·American Journal of Clinical Oncology ·Nina N. Sanford, Michael R. Folkert, Todd A. Aguilera, Muhammad S. Beg, Syed Mohammad Ali Kazmi, Aravind Sanjeevaiah, Herbert J. Zeh, Linda M. Farkas	4
9	Racial Disparities in Time to Treatment Initiation and Outcomes for Early Stage Anal Squamous Cell Carcinoma 2020 ·American Journal of Clinical Oncology ·(unknown), Muhammet Özer, Syed Mohammad Ali Kazmi, Todd A. Aguilera, Chul Ahn, David Hsiehchen, Aravind Sanjeevaiah, (unknown), Muhammad S. Beg, Nina N. Sanford	7
10	Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial 2019 ·Targeted Oncology ·Ali A. Mokdad, Hao Zhu, Muhammad S. Beg, Yull Arriaga, Jonathan E. Dowell, Amit G. Singal, Adam C. Yopp	17
11	Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer 2018 ·Journal of Gastrointestinal Oncology ·Nizar Bhulani, Arjun Gupta, Ang Gao, Jing Li, (unknown), Chul Ahn, Elizabeth Paulk, (unknown), Muhammad S. Beg	33
12	Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey 2018 ·Journal of the National Comprehensive Cancer Network ·Arjun Gupta, (unknown), Raseen Tariq, Nizar Bhulani, (unknown), (unknown), Ryan D. Frank, David H. Johnson, Sahil Khanna, Muhammad S. Beg	4
13	Feasibility of Wearable Physical Activity Monitors in Patients With Cancer 2018 ·JCO Clinical Cancer Informatics ·Arjun Gupta, Tyler F. Stewart, Nizar Bhulani, Ying Dong, (unknown), (unknown), Chad D. Rethorst, Muhammad S. Beg	36
14	A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies 2017 ·Targeted Oncology ·Trisha M. Wise‐Draper, Ganesh Moorthy, Mohamad A. Salkeni, Nagla Abdel Karim, Hala Elnakat Thomas, Carol A. Mercer, Muhammad S. Beg, (unknown), Olugbenga Olowokure, Hassana Fathallah, Sara C. Kozma, George Thomas, Olivier Rixe, Pankaj B. Desai, John C. Morris	95
15	Trends in the Incidence and Outcomes of Hospitalized Cancer Patients WithClostridium difficileInfection: A Nationwide Analysis 2017 ·Journal of the National Comprehensive Cancer Network ·Arjun Gupta, Raseen Tariq, Ryan D. Frank, Gary W. Jean, Muhammad S. Beg, Darrell S. Pardi, David H. Johnson, Sahil Khanna	23
16	Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab 2017 ·Head & Neck ·Timothy J. Brown, David J. Sher, Lucien Nedzi, Randall Hughes, Muhammad S. Beg, (unknown), Venetia Sarode, Saad A. Khan	7
17	Promise of Wearable Physical Activity Monitors in Oncology Practice 2017 ·Journal of Oncology Practice ·Muhammad S. Beg, Arjun Gupta, Tyler F. Stewart, Chad D. Rethorst	66
18	Quantification of renal steatosis in type II diabetes mellitus using dixon‐based MRI 2016 ·Journal of Magnetic Resonance Imaging ·Takeshi Yokoo, (unknown), Iván Pedrosa, Qing Yuan, Ivan Dimitrov, (unknown), Ildiko Lingvay, Muhammad S. Beg, I. Alexandru Bobulescu	33
19	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors breakdown → 2016 ·Investigational New Drugs ·Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, Mitesh J. Borad, Yoon‐Koo Kang, Jay Stoudemire, Stephen M. Smith, Andreas G. Bader, Sinil Kim, David S. Hong	682
20	Cost-Effectiveness Analysis of Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy for Anal Cancer 2014 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Muhammad S. Beg, Prajnan Das, Jeffrey Meyer	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact